MR
Matthew R Henn
DELAYED 1 MONTH
Chief Scientific Officer and EVP; President and Chief Scientific Officer
Seres Therapeutics, Inc.
Filings
2
Companies
1
Latest
May 15, 2026
Transactions
Signal
Ticker / Company
Insider
Transaction
Value
Filed
67
MCRBCLUSTER 4
Seres Therapeutics, Inc.
Matthew R Henn
Chief Scientific Officer and EVP
Sale
$580
77 sh
May 19 8:05 PM
May 18, 2026
—
Seres Therapeutics, Inc.
Matthew R Henn
Chief Scientific Officer and EVP
Option Exercise
—
238 sh
May 19 8:05 PM
May 15, 2026